Clinical Relevance of Pharmacogenetics

Drug Metabolism Reviews

Volumn 35, Issue 4, 2003, Pages 277-285

  Becquemont, Laurent ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Cytochrome P4502C9; MDR1; Pharmacogenetics; Polymorphism; Single nucleotide

Indexed keywords

ABACAVIR; ANTICOAGULANT AGENT; AZATHIOPRINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOPURINE METHYLTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT;

ALLELE; ALLELISM; BLEEDING; CARDIOTOXICITY; CLINICAL MEDICINE; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; EDUCATION; ENZYME METABOLISM; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MEDICAL SPECIALIST; METHODOLOGY; NEUTROPENIA; PHARMACOGENETICS; PREDICTION; PROTEIN EXPRESSION; RECEPTOR BINDING; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 0345731422     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-120026396     Document Type: Conference Paper

References (19)

1. Colhoun, H. M., McKeigue, P. M., Davey Smith, G. (2003). Problems of reporting genetic associations with complex outcomes. Lancet 361:865-872.
2. EMEA. (1997). Note for the Guidance on the Investigation of the Drug Interactions. http://www.eudra.org/emea.html.
3. Evans, W. E., McLeod, H. L. (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348:538-549.
4. FDA. In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. http://www. fda.gov/cder/guidance/1999.
5. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L. Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
6. Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., Scapozza, L. (2003). Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4:75-85.
7. Goldstein, D. B. (2003). Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med. 348:553-556.
8. Guttmacher, A. E., Collins, F. S. (2002). Genomic medicine - a primer. N. Engl. J. Med. 347:1512-1520.
9. Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M., Rettie, A. E. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama 287:1690-1698.
10. Hitzl, M., Drescher, S., van der Kuip, H., Schaffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., Fromm, M. F. (2001). The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293-298.
11. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., Brinkmann, U. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478.
12. Johne, A., Kopke, K., Gerloff, T., Mai, I., Rietbrock, S., Meisel, C., Hoffmeyer, S., Kerb, R., Fromm, M. F., Brinkmann, U., Eichelbaum, M., Brockmoller, J., Cascorbi, I., Roots, I. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72:584-594.
13. Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., Carlson, E. J., Herskowitz, I., Giacomini, K. M., Clark, A. G. (2003). Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481-494.
14. Little, S. J., Holte, S., Routy, J. P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S., Richman, D. D. (2002). Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
15. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., Christiansen, F. T. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
16. Rogers, J. F., Nafziger, A. N., Bertino, J. S., Jr. (2002). Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113:746-750.
17. Schwab, M., Schaeffeler, E., Marx, C., Fromm, M. F., Kaskas, B., Metzler, J., Stange, E., Herfarth, H., Schoelmerich, J., Gregor, M., Walker, S., Cascorbi, I., Roots, I., Brinkmann, U., Zanger, U. M., Eichelbaum, M. (2003). Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124:26-33.
18. Siddiqui, A., Kerb, R., Weale, M. E., Brinkmann, U., Smith, A., Goldstein, D. B., Wood, N. W., Sisodiya, S. M. (2003). Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348:1442-1448.
19. Varmus, H. (2002). Getting ready for gene-based medicine. N. Engl. J. Med. 347:1526-1527.